Opioid Rotation in a Patient with Renal Impairment and Sleep Apnea
A 57-year-old woman with metastatic breast cancer and chronic low back pain is admitted with uncontrolled pain (7/10) despite morphine ER 30 mg twice daily and immediate-release morphine 15 mg every 4 hours as needed. Labs: creatinine 2.4 mg/dL, eGFR 22, potassium 5.4. She has obesity (BMI 38), untreated obstructive sleep apnea (STOP-BANG 6), and reports new daytime somnolence and myoclonus. She is also on gabapentin 300 mg three times daily and lorazepam 1 mg at bedtime. The team asks you to optimize her analgesic regimen before discharge.
1. Identify the safety problems in the current regimen and propose a safer rotation strategy with rationale.
Read the worked answer
Problems:
- Morphine in renal impairment: Active metabolites (M6G, M3G) accumulate with eGFR 22, causing sedation, myoclonus, and respiratory depression - consistent with her exam.
- Sedative stacking: Gabapentin + benzodiazepine + opioid markedly increases respiratory depression risk, especially with untreated OSA.
- Hyperkalemia warrants attention but is not directly opioid-related.
Rotation strategy:
- Rotate off morphine to an agent less dependent on renal clearance. Hydromorphone has renal-cleared metabolites but is generally preferred over morphine in renal failure; fentanyl (hepatic metabolism, no active renally cleared metabolites) is often the safest choice for severe cancer pain, especially with renal impairment.
- Use conservative equianalgesic conversion and reduce the calculated dose by 25–50% for incomplete cross-tolerance, then titrate.
- Taper/discontinue lorazepam where feasible; reassess gabapentin dose for renal impairment (needs reduction at eGFR 22).
- Arrange OSA evaluation/treatment (CPAP) and consider palliative care involvement.
Judgment call: Prioritize safety over rapid dose escalation; document rationale and monitoring plan.
2. How would you monitor this patient after rotation, and what would trigger a change in plan?
Read the worked answer
- Monitoring: Respiratory rate, sedation scale (e.g., POSS), pain scores, myoclonus, and mental status at regular intervals; pulse oximetry if available. Recheck renal function and electrolytes.
- Triggers for change: Increasing sedation, declining respiratory rate, new confusion, or worsening myoclonus suggest accumulation or oversedation - reduce dose and reassess agent.
- Discharge plan: Clear written instructions, naloxone consideration per risk, follow-up within 48–72 hours, and coordination with oncology/palliative care.
Judgment call: The combination of renal failure, OSA, and sedatives makes this a high-risk discharge; a structured monitoring and follow-up plan is as important as the drug choice.